

## Epidemiology of HCC in Brazil: incidence and risk factors in a ten-year cohort

Denise C. Paranaguá-Vezozzo,<sup>\*,\*\*</sup> Suzane K. Ono,<sup>\*,\*\*</sup> Mónica V. Alvarado-Mora,<sup>\*,\*\*</sup>  
Alberto Q. Farias,<sup>\*,\*\*</sup> Marlone Cunha-Silva,<sup>\*\*</sup> João I. D. França,<sup>\*\*</sup>  
Venancio A. F. Alves,<sup>\*,\*\*\*</sup> Morris Sherman,<sup>\*\*\*\*</sup> Flair José Carrilho,<sup>\*,\*\*</sup>

\* São Paulo Clínicas Liver Cancer Group. \*\* Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, SP, Brazil.

\*\*\* Department of Pathology, University of São Paulo School of Medicine, São Paulo, SP, Brazil.

\*\*\*\* Department of Gastroenterology, University of Toronto and University Health Network, Toronto, Canada.

### ABSTRACT

**Background and aim.** The lack of information about hepatocellular carcinoma (HCC) in Brazil weakens health policy in preventing deaths from the illness. The aim of this study was to establish the cumulative incidence and the risk factors for hepatocellular carcinoma development in patients under a surveillance program. **Material and methods.** 884 patients with compensated cirrhosis were prospectively followed up for at least five years, from August 1998 until August 2008, with at least one annual ultrasonography liver examination and serum alpha fetoprotein (AFP) measurement. **Results.** Among 884 patients, 72 (8.1%) developed a tumor with a median follow up of 21.4 months. In the hepatocellular carcinoma group, hepatitis C virus infection was the major etiological factor (65.3%), 56.9% (41/72) were male and the mean average age was  $57 \pm 10$  years. The annual incidence of hepatocellular carcinoma was 2.9%. 79.2% (57/72) of HCCs were detected within Milan Criteria, and the mean survival time was 52.3 months, significantly higher than for those outside Milan, with a mean time of 40.6 months ( $p = 0.0003$ ). **Conclusion.** The annual incidence of HCC among this large series of Brazilian cirrhotic patients was around 2.9% with a detection rate of 8.1%, or a cumulative incidence rate over five years of 14.3%. The three variables related to HCC risk were low serum albumin [HR: 0.518 (0.46-0.78)], high AFP > 20 ng/mL [HR: 3.16 (1.86-5.38)], and ethnicity (Brazilian-East Asian descendants vs. other mixed Brazilian ethnicities) [HR: 2.86 (1.48-5.53)].

**Key words.** Ultrasonography. Milan criteria. Risk factors. Hepatocellular carcinoma. Surveillance.

### INTRODUCTION

The incidence of hepatocellular carcinoma (HCC) is rising throughout the world, ranging from 2 to 3% of cirrhosis in Western up to 6 to 11% in East Asian countries.<sup>1</sup> Men are affected three times as often as women.<sup>2</sup>

The major risk factors for HCC include chronic infections with the hepatitis B (HBV) or C (HCV) virus. However, alcohol abuse, non-alcoholic steatohepatitis (NASH) and other causes of cirrhosis can

be considered other risk factors for HCC.<sup>2</sup> Indeed, 70-90% of HCCs develop in cirrhotic patients.<sup>3,4</sup> In addition, the risk of HCC in patients with cirrhosis depends on the activity and duration of the inflammatory process underlying the cirrhotic process. The leading cause of HCC varies according to environmental factors.

However, to date, the incidence of HCC and major risk factors in Brazil are unknown. We conducted this prospective study with the aim of determining the incidence and risk factors for HCC in a large cohort of Brazilian patients with cirrhosis, with long-term follow up.

### MATERIAL AND METHODS

#### Patients

The current study was performed with outpatients from the University of São Paulo School of Medicine, the largest referral center for hepatology in Brazil, from January 1998 to August 2008.

Correspondence and reprint request: Denise C. Paranaguá-Vezozzo, M.D., Ph.D, assistant doctor

Hepatology Branch, Dept. of Gastroenterology, University of São Paulo School of Medicine. Av. Dr. Enéas de Carvalho Aguiar, 255, 05403-000 São Paulo-SP, Brazil.

Phone and fax number: +55 (11) 2661-7830

E-mail: denise.vezozzo@hc.fm.usp.br, denise.paranagua@gmail.com

Manuscript received: February 05, 2014.

Manuscript accepted: April 07, 2014.

### Study design

We initially enrolled 1,375 cirrhotic patients recruited during 5 years, classified as follows according to the etiology:

- Hepatitis C, defined by anti-HCV (+) and HCV-RNA (+).
- Hepatitis B, defined by HBsAg (+) and HBV-DNA (+).
- Alcohol abuse, by an intake of more than 60 g of ethanol/day (females) or more than 80 g of ethanol/day (males), for more than 10 years.
- NASH, by the presence of metabolic syndrome, diagnosed as reported elsewhere,<sup>5</sup> or by biopsy and miscellaneous (other factors, including cryptogenic cirrhosis and viral co-infection).

To ensure that patients involved in this study were initially free of tumor, we excluded 491 patients whose last ultrasonography (US) was more than 6 months prior to inclusion. Whenever clinically indicated, histological diagnosis from 14 Gauge needle biopsy was adopted. The presence of underlying cirrhosis was assessed histologically in 312/884 patients (35.3%) or by clinically significant portal hypertension in 572/884 patients (64.7%).

Thus, our study sample was composed of a cohort of 884 patients aged 17-84 years with compensated cirrhosis who were tumor, ascites and jaundice free at time zero.

The liver ultrasonography exams were performed by the same operator (DCPV).

### Follow up and tumor staging

Patients were followed up for at least 60 months or until death up to August 2008 for HCC tumor development with US examinations and serum AFP levels. The patients were followed up by ultrasonography exams alone and AFP levels were checked at entry and at time of diagnosis. When we took patient adherence issues into account, most of our sample (74.7%) received their US scans within 12 months. A sub analysis was also performed of the 660 patients in this subset, while the other 224 patients were unable to complete regular surveillance.

We registered a minimum of four checkpoints for each patient:

- Pretest time (1,375 patients enrolled).
- Time zero or Baseline (those who fulfilled the inclusion criteria).

- Diagnosis time (period of development of the HCC), and
- Final time (final US, or censored data (which occurs if a patient withdraws from a study, i.e. is lost from the sample before the final outcome is observed), or time of mortality in relation to the time zero checkpoint).

It is relevant to note that many patients were also evaluated in between checkpoints 2 and 3, checkpoints 3 and 4, or checkpoints 2 and 4; since these examinations did not correspond to a checkpoint within the study, they were computed but not considered.

Any presumed HCC lesion detected by US at time of diagnosis was confirmed by at least one of the following diagnostic criteria: positive histology, or two imaging techniques compatible with HCC (computed tomography and magnetic resonance with arterial enhancement and washout), or one of the previously mentioned imaging results (any technique) suggestive of HCC plus serum AFP levels > 400 ng/mL.<sup>6</sup>

### Incidence and risk factors

Additional data recorded included: gender, age, ethnic origin, etiology of cirrhosis, size and number of nodules, presence of macroscopic tumorous thrombosis, time of follow up, interval between US exams, and blood laboratory analysis. Laboratory analysis included: platelet count, albumin, bilirubin, creatinine, glucose, international normalized ratio (INR) and serum AFP. Laboratory data were obtained at time zero and at time of diagnosis from patient medical records. We also calculated the mathematical model for end-stage liver disease (MELD) score for all the patients.<sup>7</sup> Detected tumors were also classified as within or outside the Milan Criteria.<sup>8</sup>

The cumulative annual incidence included all 884 patients (812 HCC-free patients and 72 HCC patients). However, some patients were censored at the time of liver transplantation (OLT) (1.4%), developed other tumors (0.7%), died due to causes unrelated to liver cirrhosis (4.6%) or were lost before follow up (22.2%).

### Statistical analysis

Pearson  $\chi^2$ , Fisher exact, Mann-Whitney, and Student-t tests were used to evaluate differences in demographic, clinical, and etiologic features of the patient groups and tumor characteristics.

Survival time was calculated using the Kaplan-Meier method and survival curves were compared using the log-rank test. The survival times of HCC patients were analyzed starting from the time of enrollment.

The association between different variables and the development of HCC over time was assessed using univariate Cox analysis. Multivariate analysis with a backward stepwise method and Cox proportional hazards regression analysis were performed with variables that attained a  $p$  value  $< 0.1$  in a univariate analysis. In order to avoid the common problems of over fitting and collinearity, several different models were created with variables that were statistically significant in a univariate analysis ( $p < 0.1$ ) or were clinically relevant. The modeling strategy used in this study was based on a reduction in the likelihood ratio (-2LL) of the different models developed and the number of variables in each model. The lower the value of -2LL, the more explanatory power the model has over variability in the data. A  $p$  value of 0.05 or less was considered statistically significant.

Statistical analyses were made using the "R" program and its extensions and SPSS 18, Copyright IBM Corporation 2010, IBM Corporation, Route 100, Somers, NY 10589, U.S.A.

### Ethical considerations

This study was approved by the Institutional Ethics Review Board and patients signed an informed consent form of their own free will.

## RESULTS

### Study population

As shown in table 1, the majority of the 884 compensated cirrhotic patients included in this study were men, with a mean age of 55. Between 1998 and 2008, 72 (8.1%) patients developed HCC (HCC patients) with a median of diagnosis time of 21.4 months (a minimum of 6 months and maximum of 59.0 months). Thirty-six of these patients were still alive at the end of the study.

Most patients, 79.2% (57/72), were classified within the Milan Criteria and 70.8% (51/72) displayed single nodules, 33.3% (24/72) of which were less than 20 mm in diameter (Table 1). The median size of all tumors was 21 mm (8-92 mm, SD 8.45 mm). HCC diagnosis was confirmed by histology in 33.3% of the cases, the use of two imaging methods

in 59.7%, and by imaging plus serum AFP levels in 7%. HCV was the major etiological factor of HCC, in 65.3% of patients, as well as cirrhosis in 56.9% of patients at baseline. In Brazil, the cut-off MELD score to list a patient for liver transplantation is 16. Thus, at time zero, 82 patients (9.3%) had MELD scores  $> 16$ , whereas in the HCC group, 10 (13.9%) had MELD scores  $> 16$  ( $p = 0.327$ ).

Barcelona Clinic Liver Cancer staging (BCLC) was adopted in the HCC patients and was distributed as follows: BCLC-A (79.2%), BCLC-B (12.5%) and BCLC-C (8.3%). The treatments performed were (Figure 1):

- 16.6%: liver transplantation (LT).
- 7.0%: resection.
- 44.5%: percutaneous ethanol injection (PEI).
- 12.5%: transcatheter arterial chemoembolization (TACE); and
- 19.4%: palliative care.

Approximately 10% of HCC-free patients and 27.8% of HCC patients had initial AFP levels above 20 ng/mL (reference value for increased risk of HCC development) (Table 1).

One hundred and ninety-seven out of the 884 (22.2%) were lost before follow up. The mean MELD value of these patients was MELD 11.4 at entry.

### Incidence and risk factors

The annual incidence of HCC was 2.9%. The cumulative incidence increased from 1.7% at year one to 5.9% at year two, 8.6% at year three, 12.4% at year four and 14.3% at year five (Figure 2). HCV patients presented the highest overall incidence rate with 16.9%, followed closely by HCB group with 15.3%. The smallest rate was found in the NASH with 4 % and ethanol group with 5.7% of HCC over five years and finally, the miscellaneous etiology group with 7.7% in the same period. 79.2% (57/72) of HCCs were detected within Milan Criteria, and the mean survival time was 52.3 months, significantly higher than for those outside Milan, with a mean time of 40.6 months ( $p = 0.0003$ ).

Among the adherence group, 55/660 (8.3%) developed HCC over the five year period, and the cumulative incidence rate was 13.9%, of this group 80% fell within the Milan criteria and 20% outside. The overall mean survival curve of HCC patients over five years within the Milan Criteria was 52,6 compared to 38,5 months outside Milan Criteria,  $p < 0.001$ .

Figure 3 compares the cumulative survival rates of HCC-free and HCC patients (patients that will have HCC) under the present prospective surveillance program ( $p < 0.001$ ). The 5-year survival rate of HCC-free patients was 80%, whereas the 5-year survival rate of HCC patients was 53.2%.


In a univariate analysis, 6 of 8 variables showed statistical significance ( $p < 0.05$ ): serum albumin, platelet count, MELD score, ethnicity (mixed Brazilian ethnicity or Brazilian-East Asian descend-

ants), viral etiology (yes/no), and serum AFP ( $> 20$  ng/mL). Age and gender were considered control variables. The factors related to higher annual incidence of HCC were: East Asian ethnicity, serum albumin level and serum AFP dosage  $> 20$  ng/mL, which remained independent predictors of the development of HCC during follow up in a multivariate analysis. This model had the lowest likelihood ratio (-2LL) with the smallest number of variables (Table 2).


**Table 1.** Epidemiologic and clinical features of a) 812 HCC-free patients at time zero for HCC surveillance and b) 72 patients at the time of diagnosis of HCC (HCC patients).

Patient features	Non HCC n = 812		HCC n = 72	
Males (n, %)	475	58.5	41	56.9
Mean age, yr (range)	55	(17-84)	57	(26-78)
Ethnicity (Brazilian- East Asian descendants) (n, %)	43	5.3	11	15.3
Median MELD <sup>†</sup> score (range)	10	(6-26)	11	(6-34)
Median bilirubin (mg/dL) (range)	1	(0.1-24)	1.3	(0.3-16.7)
Median INR <sup>‡</sup> (range)	1.2	(0.8-3.6)	1.3	(1-5.4)
Median Albumin (g/L) (range)	4.0	(0.3-5.4)	3.6	(0.5-4.7)
Median Platelets ( $\times 10^3$ /mm <sup>3</sup> ) (range)	126	(2.7-904)	94.5	(13-377)
Median AFP <sup>§</sup> (ng/mL) (n, %)				
$\leq 20$ ng/mL	705	86.7	50	69.4
$> 20$ ng/mL	90	8.6	20	27.8
No data	37	4.4	2	2.8
Risk factors (n, %)				
Chronic hepatitis C	462	56.9	47	65.3
Chronic hepatitis B	133	16.4	16	22.2
Alcohol	124	15.3	5	6.9
NASH <sup>¶</sup>	26	3.2	1	1.4
Miscellaneous	67	8.3	3	4.2
MELD <sup>†</sup> (n, %)				
$\leq 16$	715	88	62	86.1
$> 16$	72	8.9	10	13.9
No data	25	3.1	—	—
Number of nodules (n, %)				
Single	—	—	51	70.8
Multiple	—	—	—	20.9
Thrombosis	—	—	6	8.3
Single tumor nodule (n, %)				
$\leq 20$ mm	—	—	24	33.3
$> 20$ and $\leq 30$ mm	—	—	16	22.2
$> 30$ and $\leq 50$ mm	—	—	9	12.5
$> 50$ mm	—	—	2	2.8
Included in Milan Criteria (n, %)				
Yes	—	—	57	79.2
No	—	—	15	20.8


<sup>†</sup>MELD: model for end-stage liver disease score. <sup>‡</sup>International normalized ratio. <sup>§</sup>AFP: alpha-fetoprotein. <sup>¶</sup>NASH: non-alcoholic steatohepatitis.



**Figure 1.** Treatment of the 58/72 patients with HCC identified during surveillance according to BCLC staging. BCLC stages (A-C). PEI: percutaneous ethanol injection. TACE: transcatheter arterial chemoembolization.



**Figure 2.** Cumulative annual incidence rates of the HCC patients under surveillance. A. Pre-test time = 1375 cirrhotic patients initially recruited (1998-2003) at the University of São Paulo School of Medicine. B. Time zero = 884 cirrhotic patients who were selected after 6 months for being hepatocellular carcinoma, ascites and jaundice free. The annual calculated cumulative incidence is plotted in the graph. The follow up time was from 1998 till 2008 and was always calculated with the numerator the n cases HCC in the time n divided by the patients at risk in the time n-1.



**Figure 3.** Cumulative survival rates of 812 HCC-free patients compared with 72 HCC patients under prospective surveillance ( $p < 0.001$ ). Follow up time was 60 months.

### DISCUSSION

To investigate the incidence of HCC in cirrhotic patients and the risk factors associated with it in Brazil; we prospectively evaluated a cohort of 884 cirrhotic patients using US, AFP levels, and clinical parameters in a follow up lasting 5–10 years.

Examination of the incidence of HCC in cirrhotic patients revealed remarkable gender and age variations in Brazil. In our cohort, from the largest Brazilian public referral center receiving patients from all over the country, men were more likely to be affected than women, a finding similar to that report-

ed in studies performed in the USA, Japan, and Italy.<sup>3</sup> Likewise, HCV was the main etiology of the cirrhosis and HCC. This observation is supported by Carrilho, *et al.*<sup>4</sup> who reported HCV as the most common etiology of liver cirrhosis and HCC development in Brazil. Prior to this, Brazil was considered to have a low prevalence of HCC and HBV was thought to be the most common cause of liver disease.<sup>9</sup>

Studying an Italian cohort, Sangiovanni, *et al.*<sup>10</sup> identified the mean age of diagnosis of HCC patients as 61 years. In a study in Taiwan, age at diagnosis varied between 50 and 79 years.<sup>11</sup> In the United States more than 60% of all HCC patients are 65 or older.<sup>12</sup> In a recent Japanese nationwide survey, the mean age of incidence of HCC was 66.6 years.<sup>13</sup> In our cohort the mean age of a patient with cirrhosis was 55 and HCC development 57 years, suggesting a younger age of the onset of cirrhosis and HCC de-

**Table 2.** Risk factors related to a higher incidence of HCC found in this cohort of patients: seven modeling strategies.

Variables introduced	Final model	Regression coefficient (SD)	HR† (95%CI)	p value	-2LL‡
<b>All variables (Age, gender, AFP<sup>§</sup> &gt; 20, ethnicity, platelets, virus, albumin, MELD<sup>¶</sup>)</b>	<b>AFP<sup>§</sup> &gt; 20</b>	1.151 (0.271)	<b>3.16</b> (1.86 - 5.38)	<b>&lt; 0.001</b>	<b>835.2</b>
	<b>Ethnicity</b>	1.052 (0.335)	<b>2.86</b> (1.48 - 5.53)	<b>0.0017</b>	
	<b>Albumin</b>	-0.518 (0.135)	<b>0.59</b> (0.46 - 0.78)	<b>0.0001</b>	
Platelets (x10 <sup>3</sup> /mm <sup>3</sup> )	Platelets	-0.004 (0.002)	0.99 (0.99 - 1.00)	0.0112	881.1
Virus (yes/ no)	Virus	0.703 (0.358)	2.02 (1.00 - 4.07)	0.0495	
Ethnicity (Brazilian-East Asian descendants)	Ethnicity	1.093 (0.330)	2.98 (1.56 - 5.70)	0.0009	
Platelets (x10 <sup>3</sup> /mm <sup>3</sup> )	Platelets	-0.004 (0.002)	0.99 (0.99 - 1.00)	0.0274	849.5
Virus (yes/ no)	AFP > 20	1.289 (0.265)	3.63 (2.15 - 6.11)	< 0.001	
AFP > 20 ng/mL					
Virus (yes/ no)	Virus	0.825 (0.363)	2.28 (1.12 - 4.64)	0.0229	872.6
Albumin (g/L)	Albumin	-0.600 (0.133)	0.54 (0.42 - 0.71)	< 0.001	
Ethnicity (Brazilian-East Asian descendants)	Ethnicity	1.093 (0.330)	2.98 (1.56 - 5.70)	0.0009	
Virus (yes/no)	Albumin	-0.492 (0.135)	0.61 (0.47 - 0.80)	0.0003	843.4
Albumin (g/L)	AFP > 20	1.231 (0.265)	3.42 (2.04 - 5.77)	< 0.001	
AFP > 20 ng/mL					
Albumin (g/L)	Albumin	-0.496 (0.131)	0.61 (0.47 - 0.79)	0.0001	883.3
Platelets (x 10 <sup>3</sup> /mm <sup>3</sup> )	Platelets	-0.004 (0.002)	1.00 (1.00 - 1.00)	0.0430	
Albumin (g/L)	Albumin	-0.492 (0.135)	0.61 (0.47 - 0.80)	0.0003	843.4
Platelets (x10 <sup>3</sup> /mm <sup>3</sup> )	AFP > 20	1.231 (0.265)	3.43 (2.04 - 5.76)	< 0.001	
AFP > 20 ng/mL					

† HR: hazard ratio. ‡ -2LL: likelihood ratio. § AFP: alphafetoprotein. ¶ MELD: model for end-stage liver disease score.

velopment in the Brazilian population. The earlier emergence of cirrhosis and HCC observed in Brazil may be due to restricted access to appropriate antivirals for treating HCV-positive patients in comparison with the treatments employed in more developed countries. Another explanation could relate to the prevalence and early acquisition time of the major HCC risk factors (HCV, HBV, and alcohol induced liver disease) in Brazil in comparison to developed countries, where they tend to be much later.<sup>14</sup> In any case, studies have suggested an increase in the incidence rates of HCC in all age groups among all populations. It has further been suggested that carcinogenic factors may have affected various generations of birth cohorts early in life and led to increased HCC risk.<sup>15</sup>

Our results show that the annual incidence of HCC of the population in Brazil is 2.9% (Figure 2). A similar rising trend and incidence rate (3%) was reported by Sangiovanni, *et al.*<sup>10</sup> while studying a Milanese cohort. Indeed, our sample

showed the same proportions of etiology (HCV, HBV, alcohol) as Sangiovanni's work. HCC incidence in the United States is also rising: in the period 1981-1985 it was 9.6 per 100,000 whereas by 1991-1995 the incidence was 15.2 per 100,000 (16). In Japan, HCC has reached almost 40/100,000 population with 80% caused by HCV infection.<sup>17</sup>

We found that approximately 50% of HCC patients survived for 5 years, a higher number than suggested by Sangiovanni, *et al.*<sup>10</sup> This could be due to differences and more recent advances in the therapeutic strategies employed with these patients. In addition, the Milan criteria analysis showed a significant difference in relation to survival at 60 months, i.e. 52.3 compared to 40.6 months ( $p = 0.0003$ ). Although we could not perform a rigid surveillance program in all patients, we have shown herein that, in real life conditions, maintaining the patients under screening even under sub-optimal conditions was also very helpful, still yielding rather

early detection. On the other hand, clinical outcomes are still poor when compared with other tumor types, the morbidity and mortality rate of patients with HCC is rising.<sup>18</sup>

The detection rate of small HCC tumors nowadays is comparable with some Japanese centers,<sup>17</sup> since we detected tumor nodules with a mean size of 26 mm in 92% of our HCC group. Indeed, we performed research in 2005 (unpublished) on patients outside the surveillance programme. Only 47.3% of the HCC patients were classified as within Milan criteria. Also, during three different periods, the statistics are as follows: from 1988-1993 only 31.7% of HCC were detected within Milan criteria; from 1993-1998 this ratio increased to 61.8% and finally from 1998-2005, with the maturity of the surveillance program among the cirrhotic patients of the Gastroenterology Department, the best numbers were achieved, with 85.7% of HCC patients within Milan criteria.

We observed that 8.3% of patients developed tumors in the advanced stages, as suggested by the presence of thrombus. We think that these rates will occur in a population even when patients are submitted to frequent and effective surveillance programs. Among our research group, Kikuchi, *et al.*<sup>19</sup> reported 3 cases with vascular invasion in 74 nodules smaller than 30 mm.

The detection rate of HCC was 8.1% (72/884). In a multivariate analysis, 3 variables were related to HCC risk including low serum albumin, high AFP > 20 ng/mL, and ethnicity (Brazilian-East Asian descendants versus other mixed Brazilian ethnicities). According to the model strategy adopted, from a total of seven models, five of them presented serum albumin as a common variable and predictor of HCC development. This result is in agreement with Ripoll, *et al.*,<sup>20</sup> who reported that low albumin levels are indicative of the severity of liver disease, poor liver function and a greater risk of developing HCC. We calculated an annual incidence of HCC among a large series of Brazilian cirrhotic patients of around 2.9%/year with frequency of 8.1%. Therefore, AFP measurement, while not yet recommended by the European guidelines,<sup>21</sup> remains in common clinical practice for surveillance of patients at risk of HCC. Singal, *et al.*<sup>22</sup> explored the benefit of adding AFP measurement with US for the detection of early HCC in a meta-analysis. The same group published more recently that patterns of AFP over time are independently associated with HCC.<sup>23</sup> Nonetheless, as was mentioned, in our cohort only 7% and 55% of the

patients with HCC had AFP > 400 and > 20 ng/mL, respectively, at the time of diagnosis. Thus, AFP levels alone rather than as a factor in a dynamic evaluation may, in fact, be a weak tool for HCC diagnosis. However, it may also be very helpful in selecting patients at a higher risk of HCC development or with poor prognoses, because we found higher AFP levels in patients outside the Milan Criteria (albeit without significant differences between the groups). Further studies on the relevance of using AFP in risk surveillance for HCC development and prognosis are warranted. Finally, the ethnicity variable caught our attention, because 50.0% (8/16) of patients with HBV infection and HCC were Brazilian-East Asian descendants with a family history of HCC.

The present study, a pioneer in Latin American populations, showed that the mean annual incidence of HCC among this large series of Brazilian cirrhotic patients is around 2.9%/year with a frequency of 8.1%. The factors related to a higher annual incidence of HCC were: East Asian ethnicity, serum albumin level, and serum AFP dosage > 20 ng/mL, which remained independent predictors of the development of HCC during the follow-up in a multivariate analysis. Also, 79.2% of the HCC patients were detected within the Milan Criteria, and the mean survival curve was 52.3 compared to 40.6 months for those outside the Milan Criteria.

## ABBREVIATIONS

- **2LL:** likelihood ratio.
- **BCLC:** Barcelona clinic liver cancer.
- **HBV:** hepatitis B.
- **HCC:** hepatocellular carcinoma.
- **HCV:** hepatitis C.
- **HR:** hazard ratio.
- **INR:** international normalized ratio.
- **MELD:** model for end-stage liver disease.
- **NASH:** non-alcoholic steatohepatitis.
- **OLT:** liver transplantation.
- **TACE:** transcatheter arterial chemoembolization.
- **US:** ultrasonography.

## ACKNOWLEDGEMENTS

We are deeply indebted to Dr. Mauro Tomoyuki Taniguchi for offering data from the São Paulo Municipality obituary service, undergraduate student Larissa Aragão for collecting histology data, Aline Siqueira Ferreira for revising the manuscript and

the Alves de Queiroz Family Fund for Research for its continuing sponsoring support.

## GRANT SUPPORT

The study was supported in part by Alves de Queiroz Family Fund for Research.

## REFERENCES

- Colombo M. Should patients with chronic viral hepatitis be screened for hepatocellular carcinoma? *Viral Hepatitis Rev* 1995; 1: 65-75.
- Yang JD, Roberts LR. Hepatocellular carcinoma: A global view. *Nat Rev Gastroenterol Hepatol* 2010; 7: 448-58.
- Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. *Oncologist* 2010; 15: 5-13.
- Carrilho FJ, Kikuchi L, Branco F, Goncalves CS, Mattos AA, Brazilian HCCSG. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. *Clinics* 2010; 65: 1285-90.
- Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? *Braz J Med Biol Res* 2009; 42: 958-62.
- Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; 53: 1020-2.
- Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; 33: 464-70.
- Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; 334: 693-9.
- Goncalves CS, Pereira FE, Gayotto LC. Hepatocellular carcinoma in Brazil: report of a national survey (Florianopolis, SC, 1995). *Rev Inst Med Trop Sao Paulo* 1997; 39: 165-70.
- Sangiovanni A, Del Ninno E, Fasani P, De Fasio C, Ronchi G, Romeo R, Morabito A, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. *Gastroenterology* 2004; 126: 1005-14.
- Jan CF, Chen CJ, Chen HH. Causes of increased mortality from hepatocellular carcinoma in high incidence country: Taiwan experience. *J Gastroenterol Hepatol* 2005; 20: 521-6.
- Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. *Hepatology* 2010; 52: 132-41.
- Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M. Etiology of liver cirrhosis in Japan: a nationwide survey. *J Gastroenterol* 2010; 45: 86-94.
- Coelho GR, Vasconcelos KF, Vasconcelos JB, Barros MA, Costa PE, Borges GC, Junior JT, et al. Orthotopic liver transplantation for hepatocellular carcinoma: one center's experience in the Northeast of Brazil. *Transp Proc* 2009; 41: 1740-2.
- El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. *Hepatology* 2002; 36: S74-S83.
- El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med* 1999; 340: 745-50.
- Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, et al. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. *Dig Dis* 2011; 29: 339-64.
- Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. *Gastroenterology* 2004; 127: S35-S50.
- Kikuchi LOO, Paranagua-Vezozzo DC, Chagas AL, Mello ES, Alves VA, Farias AQ, Pietrobon R, et al. Nodules less than 20 mm and vascular invasion are predictors of survival in small hepatocellular carcinoma. *J Clin Gastroenterol* 2009; 43: 191-5.
- Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, Planas R. Hepatic venous pressure gradient predicts development of Hepatocellular carcinoma independently of severity of cirrhosis. *J Hepatol* 2009; 50: 923-8.
- European Association for the Study of the Liver, European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; 56: 908-43.
- Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MAM, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. *Aliment Pharmacol Ther* 2009; 30: 37-47.
- Lee E, Edward S, Singal AG, Laviere MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of Alpha-fetoprotein, over time. *Clin Gastroenterol Hepatol* 2013; 11: 437-40.